Advances in Lung Cancer: From Genetic Landscape to Treatment
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".
Deadline for manuscript submissions: 20 July 2024 | Viewed by 98
Special Issue Editor
Interests: molecular pathology; lung cancer; malignant pleural mesothelioma; precision medicine; predictive biomarkers; molecular tests; next generation sequencing
Special Issue Information
Dear Colleagues,
Precision medicine, including both targeted therapies and immunotherapy, has dramatically changed and improved the clinical practice of lung cancer. To date, different molecular targets have been approved for metastatic advanced non-small cell lung cancer, mainly adenocarcinoma histotype, and more recently also for early-stage tumors. The molecular characterization of targetable alterations is mandatory to assess the best therapeutic approaches. However, in most lung cancer cases, available biological material is scarce, mainly represented by small biopsies or cytological specimens. In this context, liquid biopsy, particularly circulating cell free tumor DNA, has recently acquired great value as a complement of tissue testing. In addition, molecular investigations of lung cancer are warranted to uncover and face resistance mechanisms to therapy, and identify new predictive biomarkers. Therefore, the continuous optimization of next-generation sequencing techniques is crucial for a complete molecular analysis, including a plethora of genetic alterations from gene mutations to gene fusions and gene expression profiling.
This Special Issue of the International Journal of Molecular Sciences welcomes original articles, case reports, reviews and metanalyses on the advances in lung cancer covering the genetic landscape to treatment.
We look forward to receiving your contributions.
Dr. Rossella Bruno
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- lung cancer
- precision medicine
- predictive biomarkers
- resistance mechanisms
- targeted therapy
- immunotherapy
- molecular tests
- liquid biopsy
